The Oklahoma-UT Southwestern Hemostasis Consortium has been an active participant of the TMH CTN for the first four years of the network activity. Investigators from our consortium have had leading roles in the subgroups devoted to TIP, IIP, hemophilia, pediatric and HIT protocol development. In addition, both sites of our consortium have very effectively enrolled patients in the initial network .clinical trial, PLADO. For TTP, Dr. George was the initial co-chair of this subcommittee and remains a leader in the development of the STAR trial. His colleagues at Oklahoma, Dr. Sara Vesely and Ms. Dee Terrell, have also contributed in key roles to the STAR trial development: Dr. Vesely with biostatistical analysis and Ms. Terrell as one of the two key clinical trial coordinators developing this study. Both Drs. George and Buchanan have been leaders in the ITP subcommittee, working to develop a protocol for childhood ITP using a TPO-mimetic agent. Dr. Buchanan was the initial leader of the pediatric subcommittee, and has contributed to the development of a decision analysis protocol to determine the critical research questions for childhood ITP. Dr. Buchanan and two of our beginning faculty, Dr. Janna Journeycake at UT Southwestern and Dr. Kapil Saxena of Oklahoma have been key contributors to the development of the RICH study. When this study opens we anticipate being one of the leading sites for the clinical trial. Drs. Buchanan and Journeycake have also been very active in the development of the study to evaluate the role of rTPA in reducing central venous access device infection in patients with hemophilia. This has been a major research interest of Drs. Journeycake and Buchanan. Dr. Ravi Sarode of UT Southwestern has been a leader in the development of the protocol to determine the frequency of thromboembolism related to heparin, the HOT study, and he anticipates being the lead enrolling center for this study. The TMH CTN has brought our two university centers closer together with many collaborative interactions. A valuable outcome of the past four years has been the extension of collaborative relationship to the junior faculty members and trainees in our programs.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01HL072283-10
Application #
8137750
Study Section
Special Emphasis Panel (ZHL1-CSR-J (M1))
Program Officer
Mondoro, Traci
Project Start
2002-09-30
Project End
2014-08-31
Budget Start
2012-09-01
Budget End
2014-08-31
Support Year
10
Fiscal Year
2012
Total Cost
$160,234
Indirect Cost
$50,859
Name
University of Oklahoma Health Sciences Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
878648294
City
Oklahoma City
State
OK
Country
United States
Zip Code
73117
Lu, Kaelyn H; George, James N; Vesely, Sara K et al. (2014) Management of primary immune thrombocytopenia, 2012: a survey of oklahoma hematologists-oncologists. Am J Med Sci 347:190-4
Leissinger, C; Josephson, C D; Granger, S et al. (2014) Rituximab for treatment of inhibitors in haemophilia A. A Phase II study. Thromb Haemost 112:445-58
George, J N; Vesely, S K; Terrell, D R et al. (2013) The Oklahoma Thrombotic Thrombocytopenic Purpura-haemolytic Uraemic Syndrome Registry. A model for clinical research, education and patient care. Hamostaseologie 33:105-12
Griffin, Drees; Al-Nouri, Zayd L; Muthurajah, Darrshini et al. (2013) First symptoms in patients with thrombotic thrombocytopenic purpura: what are they and when do they occur? Transfusion 53:235-7
Deford, Cassandra C; Reese, Jessica A; Schwartz, Lauren H et al. (2013) Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood 122:2023-9; quiz 2142
Reese, Jessica A; Nguyen, Loan P; Buchanan, George R et al. (2013) Drug-induced thrombocytopenia in children. Pediatr Blood Cancer 60:1975-81
Reese, Jessica A; Muthurajah, Darrshini S; Kremer Hovinga, Johanna A et al. (2013) Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features. Pediatr Blood Cancer 60:1676-82
Triulzi, Darrell J; Assmann, Susan F; Strauss, Ronald G et al. (2012) The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia. Blood 119:5553-62
George, James N; Terrell, Deirdra R; Vesely, Sara K et al. (2012) Thrombotic microangiopathic syndromes associated with drugs, HIV infection, hematopoietic stem cell transplantation and cancer. Presse Med 41:e177-88
Josephson, Cassandra D; Granger, Suzanne; Assmann, Susan F et al. (2012) Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopenia. Blood 120:748-60

Showing the most recent 10 out of 19 publications